Equities

Alphamab Oncology

Alphamab Oncology

Actions
  • Price (HKD)4.91
  • Today's Change0.41 / 9.11%
  • Shares traded12.71m
  • 1 Year change-49.01%
  • Beta--
Data delayed at least 15 minutes, as of Nov 14 2024 05:04 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CNY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments1,4071,3501,985
Total Receivables, Net738068
Total Inventory796558
Prepaid expenses------
Other current assets, total--05.63
Total current assets1,5591,4952,117
Property, plant & equipment, net578621545
Goodwill, net------
Intangibles, net------
Long term investments------
Note receivable - long term1.051.9344
Other long term assets------
Total assets2,1372,1182,705
LIABILITIES
Accounts payable321228
Accrued expenses120141109
Notes payable/short-term debt000
Current portion long-term debt/capital leases80190464
Other current liabilities, total354236
Total current liabilities267385637
Total long term debt177155173
Total debt257345637
Deferred income tax------
Minority interest------
Other liabilities, total222024
Total liabilities465560835
SHAREHOLDERS EQUITY
Common stock0.010.010.01
Additional paid-in capital4,0533,7263,717
Retained earnings (accumulated deficit)(2380)(2168)(1847)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total(0.75)0.050.49
Total equity1,6721,5581,870
Total liabilities & shareholders' equity2,1372,1182,705
Total common shares outstanding965940937
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.